Home Effects of urine dilution on quantity, size and aggregation of calcium oxalate crystals induced in vitro by an oxalate load
Article
Licensed
Unlicensed Requires Authentication

Effects of urine dilution on quantity, size and aggregation of calcium oxalate crystals induced in vitro by an oxalate load

  • Angela Guerra , Franca Allegri , Tiziana Meschi , Giuditta Adorni , Beatrice Prati , Antonio Nouvenne , Almerico Novarini , Umberto Maggiore , Enrico Fiaccadori and Loris Borghi
Published/Copyright: July 5, 2005

Abstract

Increasing urinary volume is an important tool in the prevention of calcium renal stones. However, the mechanism of how it actually works is only partially understood. This study aimed at assessing how urine dilution affects urinary calcium oxalate crystallization. A total of 16 male idiopathic calcium oxalate (CaOx) stone-formers and 12 normal male subjects were studied and 4 h urine samples were taken twice, under low (undiluted urine) and high hydration conditions (diluted urine). An equal oxalate load (1.3mmol/L) was added to both types of urine and the crystallization parameters were assessed. In both stone-formers and normal subjects, the crystallization processes were significantly (p<0.05 or less) more marked in the undiluted urine than in the diluted urine in terms of: a) total quantity of calcium oxalate dihydrate (COD) and calcium oxalate monohydrate (COM) crystals; b) total quantity of crystalline aggregates; and c) aggregation index (i.e., ratio between the area occupied by crystalline aggregates and the area occupied by all the crystals present). The comparison between stone-formers and normal subjects showed that the greatest difference was for the size of COD crystals, which were larger in the urine of the stone-formers. A further important finding was an inverse relationship between changes in urinary volume and in the aggregation index (r=–0.53, p=0.004). In conclusion, urine dilution considerably reduces crystallization phenomena induced in vitro by an oxalate load in both calcium stone-formers and normal subjects.


Corresponding author: Loris Borghi MD, Dipartimento di Scienze Cliniche, Università di Parma, Via Gramsci 14, 43100 Parma, Italy Phone: +39-0521-702007, Fax: +39-0521-940993,

References

1 Pak CY, Sakhaee K, Crowther C, Brinkley L. Evidence justifying a high fluid intake in treatment of nephrolithiasis. Ann Intern Med 1980; 93: 36–9. 10.7326/0003-4819-93-1-36Search in Google Scholar

2 Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996; 155: 839–43. 10.1016/S0022-5347(01)66321-3Search in Google Scholar

3 Borghi L, Meschi T, Schianchi T, Briganti A, Guerra A, Allegri F, et al. Urine volume: stone risk factor and preventive measure. Nephron 1999; 81(Suppl 1): 31–7. 10.1159/000046296Search in Google Scholar

4 Borghi L, Guerra A, Meschi T, Briganti A, Schianchi T, Allegri F, et al. Relationship between supersaturation and calcium oxalate crystallization in normals and idiopathic calcium oxalate stone formers. Kidney Int 1999; 55: 1041–50. 10.1046/j.1523-1755.1999.0550031041.xSearch in Google Scholar

5 Guerra A, Meschi T, Allegri F, Schianchi T, Adorni G, Novarini A, et al. Calcium oxalate crystallization in untreated urine, centrifuged and filtered urine and ultrafiltered urine. Clin Chem Lab Med 2004; 42: 45–50. 10.1515/CCLM.2004.009Search in Google Scholar

6 Baumann JM, Affolter B, Brenneisen J, Siegrist HP. Measurement of metastability, growth and aggregation of calcium oxalate in native urine. Urol Int 1997; 59: 214–20. 10.1159/000283066Search in Google Scholar

7 Hess B, Kok DJ. Nucleation, growth, and aggregation of stone-forming crystals. In: Coe FL, Favus MJ, Pak CY, Parks JH, Preminger GM, editors. Kidney stones: medical and surgical management. Philadelphia: Lippincott-Raven, 1996:3–32. Search in Google Scholar

8 Hallson PC, Rose GA. Uromucoids and urinary stone formation. Lancet 1979; 12: 1000–2. Search in Google Scholar

9 Kok DJ, Papapoulos SE, Bijvoet OL. Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet 1986; 10: 1056–8. 10.1016/S0140-6736(86)91329-2Search in Google Scholar

10 Edyvane KA, Hibberd CM, Harnett RM, Marshall VR, Ryall RL. Macromolecules inhibit calcium oxalate crystal growth and aggregation in whole human urine. Clin Chim Acta 1987; 167: 329–38. 10.1016/0009-8981(87)90353-6Search in Google Scholar

11 Hess B, Nakagawa Y, Coe FL. Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 1989; 257: F99–F106. 10.1152/ajprenal.1989.257.1.F99Search in Google Scholar PubMed

12 Ebisuno S, Kohjimoto Y, Yoshida T, Ohkawa T. Effect of urinary macromolecules on aggregation of calcium oxalate in recurrent calcium stone formers and healthy. Urol Res 1993; 21: 265–8. 10.1007/BF00307708Search in Google Scholar PubMed

13 Hess B. Tamm-Horsfall glycoprotein and calcium nephrolithiasis. Mineral Electrolyte Metab 1994; 20: 393–8. Search in Google Scholar

14 Khan SR. Interactions between stone-forming calcific crystals and macromolecules. Urol Int 1997; 59: 59–71. 10.1159/000283025Search in Google Scholar PubMed

15 Hess B. Tamm-Horsfall glycoprotein – inhibitor or promoter of calcium oxalate monohydrate crystallization processes? Urol Res 1992; 20: 83–6. 10.1007/BF00294343Search in Google Scholar PubMed

16 Ackermann D, Brown P, Khan SR. Preparation and application of calcium oxalate dihydrate crystal seeds. Urol Res 1989; 17: 147–8. Search in Google Scholar

17 Yuzawa M, Tozuka K, Tokue A. Effect of citrate and pyrophosphate on the stability of calcium oxalate dihydrate. Urol Res 1998; 26: 83–8. 10.1007/s002400050028Search in Google Scholar PubMed

18 Berg W, Hesse A, Schneider HJ. A contribution to the formation mechanism of calcium oxalate urinary calculi. III. On the role of magnesium in the formation of oxalate calculi. Urol Res 1976; 4: 161–7. 10.1007/BF00262349Search in Google Scholar PubMed

19 Worcester EM. Urinary calcium oxalate crystal growth inhibitors. J Am Soc Nephrol 1994; 5(Suppl 1): 46–53. 10.1681/ASN.V55s46Search in Google Scholar PubMed

20 Robertson WG, Peacock M. Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone-formers. Clin Sci 1972; 43: 499–506. 10.1042/cs0430499Search in Google Scholar PubMed

Received: 2005-1-24
Accepted: 2005-3-30
Published Online: 2005-7-5
Published in Print: 2005-6-1

© Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Spectrophotometric determination of urinary iodine by the Sandell-Kolthoff reaction subsequent to dry alkaline ashing. Results from the Czech Republic in the period 1994–2002
  2. Comparison of iodine contents in gastric cancer and surrounding normal tissues
  3. Effects of urine dilution on quantity, size and aggregation of calcium oxalate crystals induced in vitro by an oxalate load
  4. Is idiopathic recurrent calcium urolithiasis in males a cellular disease? Laboratory findings in plasma, urine and erythrocytes, emphasizing the absence and presence of stones, oxidative and mineral metabolism: an observational study
  5. Circulating levels of nitrated apolipoprotein A-I are increased in type 2 diabetic patients
  6. Apolipoprotein A5 gene polymorphism –1131T→C: association with plasma lipids and type 2 diabetes mellitus with coronary heart disease in Chinese
  7. A simple method for estimating equilibrium constants for serum testosterone binding resulting in an optimal free testosterone index for use in elderly men
  8. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer
  9. Plasma homocysteine and markers for oxidative stress and inflammation in patients with coronary artery disease – a prospective randomized study of vitamin supplementation
  10. Comparison of methods for calculating serum osmolality: multivariate linear regression analysis
  11. Radioimmunoassay for plasma C-type natriuretic peptide determination: a methodological evaluation
  12. Evaluation of the Konelab 20XT clinical chemistry analyzer
  13. A guide to defining the competence required of a consultant in clinical chemistry and laboratory medicine
  14. Time course of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients presenting with acute coronary syndrome
  15. Screening for gestational diabetes mellitus
  16. Systematic terminology for specialities and disciplines related to clinical laboratory
Downloaded on 24.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2005.102/html
Scroll to top button